Eray Alper

Eray Alper

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2003 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
EAEray Alper
Eray Alper
MGM Gurel
M Gurel
TET Evrensel
T Evrensel
VOV Ozkocaman
V Ozkocaman
TAT Akbunar
T Akbunar
MDM Demi̇ray
M Demi̇ray
Technetium-99m 2-methoxyisobutylisonitrile (99mTc-MIBI) is a lipophilic agent that has been proposed as a useful tracer for the detection of disease sites in patients with multiple myeloma (MM). We performed a prospective study to determine the potential of 99mTc-MIBI imaging for the evaluation of the extent of primary disease in patients with advanced stage MM, compared with skeletal survey and bone scintigraphy. Twenty patients with advanced stage MM at initial diagnosis underwent whole-body 99mTc-MIBI imaging, together with contemporaneous skeletal survey and bone scintigraphy. The findings of 99mTc-MIBI imaging were correlated with the results of skeletal survey and bone scan. All 99mTc-MIBI scans were positive for the presence of active MM, whereas skeletal surveys were positive in 18 patients (90%) with osteolytic lesions. Bone scintigraphy demonstrated MM in only 15 patients (75%). In two patients with no detectable lesions on skeletal survey, 99mTc-MIBI imaging revealed uptake in the spine, corresponding to the abnormalities seen on magnetic resonance imaging (MRI). With respect to the localization of bone lesions, 99mTc-MIBI imaging was superior to bone scintigraphy in 15 patients (75%) and had concordant results with bone scintigraphy in four (20%). 99mTc-MIBI imaging is a very sensitive imaging modality for the identification of the extent of disease in patients with advanced MM. It is clearly superior to bone scintigraphy and complements the results of skeletal survey by finding additional disease sites. Hence, in active MM patients, 99mTc-MIBI imaging has the potential to detect bone marrow disease that cannot be detected by skeletal survey and bone scintigraphy.

1 December 2006 in Joint Bone Spine
Verified
Journal Article
Closed access
MYMerih Yurtkuran
Merih Yurtkuran
MYMustafa Yurtkuran
Mustafa Yurtkuran
AAAlev Alp
Alev Alp
KSKoncuy Sivrioglu
Koncuy Sivrioglu
KDKamil Dilek
Kamil Dilek
ANAşkın Nasırcılar
Aşkın Nasırcılar

2 July 2026 in Cancer Imaging
Verified
Journal Article
Open access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper
PSMA PET/CT has transformed prostate cancer management, yet its diagnostic utility is not absolute. It fails to detect PSMA-suppressed disease variants, including treatment-induced neuroendocrine prostate cancer (t-NEPC) and dedifferentiated tumors, and is inherently blind to second primary malignancies (SPMs). This study evaluated the additional diagnostic yield and direct clinical impact of incorporating [¹⁸F]FDG PET/CT into a systematic, indication-driven dual-tracer protocol in high-risk prostate cancer patients. In this retrospective, STROBE-compliant, single-center cohort study, 82 patients with histologically confirmed prostate cancer who underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FDG PET/CT were analyzed. Clinical indications encompassed suspected SPM, suspected dedifferentiation or t-NEPC, initial staging of very high-risk disease, pre-[¹⁷⁷Lu]Lu-PSMA therapy evaluation, and equivocal PSMA findings. The primary endpoint was the proportion of patients in whom [¹⁸F]FDG PET/CT provided additional diagnostic information. Secondary endpoints included concordance analysis and the rate of management changes. Median age was 72 years (IQR 65-75). [⁶⁸Ga]Ga-PSMA-11 demonstrated superior prostate cancer detection compared to [¹⁸F]FDG (70.7% vs. 25.6%; McNemar's p < 0.0001). However, [¹⁸F]FDG PET/CT provided clinically critical additional information and directly altered management in 51.2% of patients (95% CI: 40.6-61.7%). The most impactful contributions were histopathologically confirmed SPM detection (30.5%, predominantly lung and colorectal adenocarcinomas) and identification of PSMA-negative/FDG-positive discordant disease signaling dedifferentiation. No significant correlation was found between PSMA and FDG SUVmax values (Spearman rho = 0.149, p = 0.422), underscoring their biologically distinct and complementary targets. [¹⁸F]FDG PET/CT is not a redundant adjunct to PSMA imaging; it fills a critical diagnostic blind spot. When applied through an indication-driven framework, dual-tracer imaging directly reshapes clinical decision-making in more than half of selected high-risk prostate cancer patients, enabling detection of occult malignancies and guiding pivotal treatment decisions that PSMA PET/CT alone cannot support.

15 April 2020 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
GBGokce Belge
Gokce Belge
CBCem Bilgin
Cem Bilgin
GOGuven Ozkaya
Guven Ozkaya
SKSedat Giray Kandemirli
Sedat Giray Kandemirli
EAEray Alper
Eray Alper

1 December 2000 in European Journal of Pediatric Surgery
Verified
Journal Article
Closed access
IKİ. Kırıştıoğlu
İ. Kırıştıoğlu
TAT. Akbunar
T. Akbunar
NKN. Kılıç
N. Kılıç
IÖİ. Özel
İ. Özel
EAEray Alper
Eray Alper
HDH. Doğruyol
H. Doğruyol
We aimed to investigate the value of scintigraphically determined evacuation fraction (EVF) as an objective follow-up criterion in medically treated children with chronic constipation, and to evaluate the relation between patients' symptoms and rectal emptying rate. Thirty children (m: 22, f: 8, mean age: 8.9 +/- 0.9 year) suffering from chronic constipation were assessed by scintigraphic evacuation study. All patients underwent anal manometric and scintigraphic examinations before their therapy was started. During 3 months, they received conventional laxative treatment for constipation, and scintigraphic studies were repeated in 20 of 30 patients. Scintigraphic examinations consisted of instillation of artificial stool into the rectum up to the volume impending rectal evacuation, and acquisition of pre- and post-evacuation images. EVF values were then calculated from the images using a fixed region of interest. All of the patients had high resting anal canal pressure (75 +/- 12 mmHg) and had positive rectoanal inhibitory reflex. In 14/20 patients (70%) who benefited from therapy, mean EVF changed from 43.6% to 62.2% (p < 0.001), while decreasing in 6120 who did not benefit. The volume arousing rectal evacuation was significantly lower at the second scintigraphic study (261 +/- 98 ml) than the first study (354 +/- 138 ml) (p < 0.05). As a conclusion: 1) EVF was low in chronically constipated children, 2) it was improved after conventional laxative treatment and, 3) radionuclide EVF determination may be a useful method for follow-up.

18 February 2026 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper